Navigation Links
YM BioSciences Announces Secondary Efficacy and Safety Findings in,Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial -

MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data from its 99 patient, randomized, placebo-controlled, multi-center Phase IIb trial (DLXLEF-AP4) with AeroLEF(TM). AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. YM previously announced that this trial had successfully achieved its primary endpoint, the summed pain intensity difference/pain relief scores (SPRID4) during the 4 hours from the start of the initial dose of study medication (p=0.0194).

Additional Secondary Efficacy and Safety Findings

The treatment phase of the study began in the post-anesthetic care unit (PACU) after completion of surgery when patients reported a pain intensity score (PI) of at least 2 (moderate pain) on a 4-point verbal rating scale (0 (none) to 3 (severe pain)). The clinical trial study period was up to 12 hours and patients were allowed to self-administer AeroLEF(TM) to treat up to two additional pain episodes during the study period. For each pain episode, patients were instructed to continue the self-administration of drug until achievement of one of the following endpoints: achievement of effective analgesia, completion of full dose, or onset of dose-limiting side effects. Patients were allowed rescue medication at any time following initiation of study treatment.

For the first dose administered in the PACU, the percentage of patients reporting a pain intensity (PI) score of less than or equal to 1 (mild pain or no pain) at the end of the dosing period with AeroLEF(TM) was 59%, a statistically significant difference from placebo (27%)
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
3. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:11/18/2014)... 2014  AgeneBio, a pharmaceutical company developing innovative ... brain function, today announced that the Company,s founder ... PhD, has received the Society for Neuroscience,s Mika ... years, Dr. Gallagher,s research at Johns Hopkins and ... has led to advancements in the field of ...
(Date:11/17/2014)... Nov. 17, 2014 Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that Jane ... Development, will participate in a live Google Hangout session ... discussing the latest progress in stem cell-based therapies for ... Hangout session is scheduled for Tuesday, November 18, 2014, ...
(Date:11/17/2014)... , November 17, 2014 ... Boston on 20 November   ... discovery and development company, is pleased to announce that ... as one of ten top projects in neuroscience by ... Grau will present an overview of the programme ...
Breaking Medicine Technology:AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience's Mika Salpeter Lifetime Achievement Award 2AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience's Mika Salpeter Lifetime Achievement Award 3Asterias Biotherapeutics to Participate in Live Google Hangout Discussion of Stem Cell-Based Therapies for Spinal Cord Injury 2Heptares First-in-Class Selective Muscarinic Agonists Chosen as one of top Neuroscience Projects to Watch 2
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ("AcelRx"), a ... innovative therapies for the treatment of acute or breakthrough pain, ... ended December 31, 2010. Net loss for the ... common share, compared with a net loss of $3.7 million, ...
... 23, 2011 Actavis Group, an international generic pharmaceuticals ... the US Food & Drug Administration to market Valacyclovir ... 500mg and 1 gram, the generic equivalent of Valtrex® ... for the 12 months ending December 31, 2010, according ...
Cached Medicine Technology:AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 2AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 3AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 4AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 5AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results 6Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2
(Date:11/18/2014)... (HealthDay News) -- Cocaine users can have abnormal blood ... which can put them at increased risk for heart ... in Chicago compared heart imaging test results from 202 ... illegal drug. Those using cocaine showed subtle abnormalities ... which were considered significant when compared to non-cocaine users ...
(Date:11/18/2014)... November 18, 2014 OpenWorks, one of ... in the 2014 Lincoln Guild Invitational. The John C. ... to support the Phoenix-area Desert Mission community programs. Open ... , The tournament was held at Camelback Golf Club ... support the efforts of Desert Mission — including a ...
(Date:11/18/2014)... 2014 As children head back to ... look at fall as the perfect time to refresh ... , Orange County facial plastic surgeon, has observed a ... At the Gallery of Cosmetic Surgery he has noticed ... non-invasive cosmetic surgery procedures. , “Non-invasive cosmetic treatments ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. ... verge of burning out are more likely to develop heart ... vital exhaustion -- a toxic combination of fatigue, irritability and ... heart disease, researchers report. "In our increasingly busy lives, ... when that stress is left unchecked for a period of ...
(Date:11/17/2014)... CA (PRWEB) November 17, 2014 A ... thousands of patients throughout the country are turning back ... than ever before. This is because the company has ... to their already impressive collection of prescription and non-prescription ... who have incorporated Diet Doc’s best anti-aging ...
Breaking Medicine News(10 mins):Health News:Cocaine Can Cause Heart Problems: Study 2Health News:OpenWorks Sponsors 2014 Lincoln Guild Invitational Golf Tournament Hosted by Scottsdale's Camelback Golf Club 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 3Health News:Feeling 'Worn Out'? Your Heart May Pay the Price 2Health News:Feeling 'Worn Out'? Your Heart May Pay the Price 3Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 2Health News:Best Anti-Aging Human Growth Hormone Therapy Safely and Naturally Restores Diet Doc Patients to More Youthful Levels 3
... appearing in the February 22 issue of the Journal ... in the effectiveness of the coronary stents coated with ... be more effective in easing the examination of the ... ,Such stents also improve the prognosis or the ...
... heart failure therapy lack of conclusive evidence it supports ... support a device that uses balloon-like pants as a ... in question is called “External counterpulsation”(ECP), a noninvasive therapy ... most commonly used to relieve hard-to-treat chest pain for ...
... Northwestern University Feinberg School of Medicine is conducting a ... effective in pancreatic tumours.// ,The drug also known ... to inhibit the growth of blood vessels in tumours. ... it in combination with abdominal radiation therapy and chemotherapy ...
... (NHANES III) has studied the relation between three parameters ... carried out at the University at Buffalo has given ... a significant predictor for periodontal disease. This relation is ... ,The study finds pride of a place in a ...
... by the bird flu threat has resulted in poultry products ... capital. One can see that in Gazipur wholesale market chickens ... ,Only those chickens that were certified by the veterinary ... whereas those that were uncertified was available for a mere ...
... samples, taken from the people of Nandurbar district, is yet ... had spread to humans, even as the culling of thousands ... said the massive culling exercise in the region that reported ... be completed by early Thursday. ,India's first confirmed ...
Cached Medicine News:Health News:'Inflatable-pants' heart failure therapy suffers due to lack of evidence. 2Health News:Avastin under trial to test efficacy for pancreatic tumours! 2Health News:Periodontal disease can be predicted by trends in obesity! 2Health News:Delhi Sees Sharp Decline In Chicken Prices 2Health News:Delhi Sees Sharp Decline In Chicken Prices 3Health News:India Awaits Test Results To Confirm The Bird Flu Virus In Humans 2
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
The Intradyn Tear-Away Introducer Sheath with Spin-Lock offers a secure dilatorsheath connection, a smooth dilatorsheath transition and a clean, even tear....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Medicine Products: